FDA Approves Inovio's Voceryq for Rare Throat Disease, Recurrent Respiratory Papillomatosis

The U.S. Food and Drug Administration (FDA) has approved Inovio Pharmaceuticals' INO-3107, branded as Voceryq, for the treatment of recurrent respiratory papillomatosis (RRP). This marks Inovio's first approved product and offers a new treatment option for patients with this rare respiratory condition, which causes growths in the airways and often necessitates repeated surgeries. Voceryq is a plasmid DNA-based immunotherapy designed to generate immune responses against HPV types 6 and 11, which are primary causes of RRP. The approval was granted under the FDA's accelerated approval pathway, requiring a confirmatory study to verify clinical benefit.